SELLAS Life Sciences Group’s Phase II clinical trials of galinpepimut-S, an immunotherapeutic anti-cancer treatment, have illustrated significant benefits for those patients who have utilized it following autotransplantation with high-risk multiple myeloma, particularly those with an adverse cytogenetic profile. “We are encouraged by these positive results and planning further studies to expand upon and confirm our observations,” said Guenther Koehne, MD, PhD.
The Principal Investigator for the Phase II trial of galinpepimut-S, Guenther Koehne MD, PhD has optimistically expressed his hope that,”… immunotherapeutic strategies targeting this antigen could improve key outcomes in patients with multiple myeloma.” SELLAS Life Sciences Group Vice Chairman and CEO Dr. Angelos Stergiou affirms the positive Phase II results for acute myeloid leukemia and malignant pleural mesothelioma and prepares for Phase III trials to begin. Nicholas Sarlis, MD, PhD and SELLAS Chief Medical Officer feels that the promising statistics from a pilot clinical study in myeloid myeloma supports additional evaluation of the potential applications of galinpepimut-S in studies of patients with a poor outlook. “We are now witnessing promising responses in these high-risk patients, who typically relapse within 12-15 months of autotransplant. We are committed to more clinical research for this high unmet medical need population with our agent, aiming to understand the immunobiological mechanisms behind its positive effects,” said Dr. Sarlis.
Galinpepimut-S was developed by Sloan Kettering Cancer Center and is now licensed to SELLAS Life Sciences Group. Vice Chairman and CEO Dr. Angelos Stergiou works with the SELLAS team which is performing patient testing trials of galinpepimut-S, a late-stage cancer immunotherapy.
SELLAS’ immunotherapeutic galinpepimut-S is a late stage WT1 targeted agent licensed from Memorial Sloan Kettering Cancer Center which is undergoing research in treating multiple types of tumors.
SELLAS Life Sciences Group’s Phase II study of its galinpepimut-S immunotherapeutic in Multiple Myeloma began in 2014 with 19 patients committed to the study, according to Dr. Angelos Stergiou, Vice Chairman and CEO of SELLAS. Seventeen of the 18 patients who participated in the study who could be evaluated are still alive as of the date of reporting. Fifteen of these patients demonstrated high-risk cytogenetics with unfavorable clinical characteristics which normally result in low survival rates which do not exceed 12 to 15 months following their autologous stem cell transplantation procedures. The positive results of the Phase II study have appeared very favorably when compared with a group of multiple myeloma patients with high-risk cytogenetics reported by the MD Anderson Cancer Center, who nearly doubled their progression free survival rates in 18 months with nearly a 43% increase in OS.
Vice Chairman and CEO of SELLAS Life Sciences Group Dr. Angelos Stergiou is greatly encouraged by the positive results of the Phase II WT1 Immunotherapeutic Anti-Cancer Treatment for multiple myeloma patients, and has total confidence in the Principal Investigator in the Phase II trial for SELLAS’ galinpepimut-S immunotherapeutic, Guenther Koehne, MD, an Attending Physician for the Adult Bone Marrow Transplantation Service of SELLAS. “Treatments for high-risk multiple myeloma have remained a clinical challenge. Now, for the first time, galinpepimut-S has provided strong indication of a meaningful clinical benefit.”
Dr. Angelos Stergiou values SELLAS’ appointment of Dr. Jonathan Eckard to its executive team in light of Eckard’s experience as Director and Senior Biotechnology Analyst for Barclays, a universal bank with operations in over 50 countries and territories and 48 million customers. The most powerful transnational corporation in ownership, Barclays wields absolute corporate control over global financial stability. Dr. Eckard is enthusiastic by the Phase II trial results for galinpepimut-S. “I am encouraged by clinical data for galinpepimut-S to date and am excited to be joining SELLAS as we approach our initial Phase 3 trials. I look forward to working with the SELLAS team to maximize the potential of this exciting therapy across various indications as a monotherapy as well as combination therapy.”
Vice Chairman and Chief Executive Officer of SELLAS Life Sciences Group Dr. Angelos Stergiou, MD, ScD h.c., has recently voiced the Company’s satisfaction and prognosis for its agent galinpepimut-S immunotherapeutic’s Phase II study results, which have indicated a significant clinical benefit. “When combined with validated safety and efficacy profiles across acute myeloid leukemia and malignant pleural mesothelioma, these results underscore the ability of galinpepimut-S to target a broad range of cancer indications. Our target indications represent significant unmet medical needs, with relapse rates of more than 80%, and so we are encouraged that these data indicate a substantial improvement in survival rates.” The Company’s further Phase II study concentrated on treatment in multiple high-risk myeloma patients who have relapsed with a year of undergoing autologous stem cell transplantation, or ASCT.
SELLAS Life Sciences Group specializes in biopharmaceuticals for late stage cancer immunotherapies which cover a significant range of indication for cancer. SELLAS recently appointed Dr. Jonathan Eckard to their team as a Chief Business and Strategy Officer. Dr. Eckard has extensive Wall Street experience inasfar as the biotechnology sector is concerned. His understanding of the healthcare equity markets will go far to assist SELLAS in the development of its galinpepimut-S immunotherapeutic, an agent which has the potential to have an effect on more than 25 different types of cancer cells. Dr. Angelos Stergiou, the Vice Chairman and CEO of SELLAS, applauds the appointment. “We are delighted to have attracted a highly regarded analyst to SELLAS’ executive team. Jon’s knowledge of the biotechnology sector and immunogen-oncology will be pivotal in optimizing the company’s strategic and financial goals.”
SELLAS and founder Dr. Angelos Stergiou’s goal is to give impetus to their differentiated cancer immunotherapy program through building the strength of their management team in the finance, medical and commercial development areas. The acquisition of the expertise such as Dr. Jonathan Eckard will go far to build on the heightened interest in SELLAS’ research after the release of positive clinical data for acute myeloid leukemia, malignant pleural mesothelioma and multiple myeloma. Dr. Eckard has been dubbed the Best up-and-comer and a Rising Star by institutional Investor during his time as a research analyst. “SELLAS’ highly differentiated therapy is positioned optimally in the emerging immunogen-oncology landscape and has the potential to benefit patients across a range of different cancers,” Dr. Eckard said.
Dr. Angelos M. Stergiou, MD is an entrepreneurial scientist and physician who founded SELLAS Life Sciences Group in 2012. He is now pioneering cancer vaccination research and working on a promising drug, known as the WT1 cancer vaccine (galinpepimut-S), that could save countless lives worldwide.
The lifelong dream of Dr. Angelos Stergiou has been to help others. In his own words, he has “always wanted to give back to humanity, and without clinical research, discovery and drug development, [the world] would not have new drugs.” By applying his personal passion for biotechnology to his expertise as a physician, Dr. Stergiou is fulfilling his dreams.
Also Read: http://finance.yahoo.com/news/sellas-life-sciences-appoints-former-133000326.html
If you aspire to help people as a physician as well, and you exhibit traits like those touched on below, you might be in need of a career change…
- Patients and peers alike enjoy working with physicians who are straightforward about facts. Medical professionals require the ability to be forthcoming and honest, even when delivering bad news.
- Without passion, patients and fellow physicians are likely to assume that you do not care about your career as a medical professional. Ideal physicians should be passionate and enthusiastic about their lines of work, and about the health of all that they come into contact with.
Whether you would like to focus on biotechnology, as Dr. Angelos M. Stergiou does, or you would like to work as a family doctor in a small practice, your first step to beginning a career is to have passion for what you are doing.
Dr. Angelos M. Stergiou, MD, ScD h.c. founded SELLAS Life Sciences Group with Dr. Miltos K. Sugiultzoglu, a friend and colleague. Through the company, the two have pioneered the cancer vaccine industry with a strong team behind them and promising early-phase trials for SELLAS Life Sciences Group products.
The WT1 cancer vaccine has received media coverage, praising and examining its potential for cancer patients on multiple occasions, and it is currently the main focus of the company. When speaking about the vaccine in a 2016 interview with Kentucky Wesleyan College, Dr. Angelos Stergiou stated that “We are entering pivotal Phase 3 studies and have an exciting path ahead of us.” He then touched on his aspirations for the company, noting that his “eventual goal is to build SELLAS into a global immunotherapy company.”
The focus of SELLAS Life Sciences is on pioneering novel cancer therapeutics and on developing best-in-class approaches, aiming to improve the lives of patients with innovative treatments.
Visit http://www.slideshare.net/AngelosStergiou/angelos-stergiou-about-sellas-life-sciences-group to know more about him.
Dr. Angelos M. Stergiou, MD, ScD h.c. is a physician, scientist, entrepreneur, inventor and the Vice Chairman and CEO of SELLAS Life Sciences Group. He is presently working on a number of novel products through his company, the most notable of which is the WT1 cancer vaccine, and his goals of giving back to humanity are becoming reality.
If you, as many modern professionals are, find yourself inspired by the accomplishments of medical practitioners like Angelos Stergiou, medicine might be the right field for you. Reasons below are just some of the most common:
- Endless Opportunity. Upon graduation, medical professionals are met with a broad range of employment opportunities. You can select from the opportunities available or, if you see an untapped or unexplored field, you can combine existing areas of study to make your own. Over the course of your education, you will discover interests that will help you narrow your available options to select the most rewarding path.
- Helping Others. Professionals like Dr. Stergiou often enter medicine to help others, and they are not left wanting. In a 2016 interview about his career, Stergiou stated: “I have always wanted to give back to humanity.” Later in the interview, when touching on the success of his company and the potential of the WT1 cancer vaccine, he said: “The thirst to . . . get this approved, so we can potentially save lives, is breathtaking.”
The above quotes are just one of countless examples of medical professionals finding satisfaction in helping others. Pursuing such a career path could allow you to join their ranks.
Before you begin your career and follow the footsteps of professionals like Dr. Angelos M. Stergiou, take time to speak with universities, do more research and consider your motivations. Though a medical career is rewarding, you must be passionate to succeed.